Feasibility Study of Low Level Light Therapy for Prevention of Oropharyngeal Mucositis in Pediatric Transplants Patients
| Status: | Completed |
|---|---|
| Healthy: | No |
| Age Range: | 4 - 25 |
| Updated: | 1/27/2017 |
| Start Date: | April 2014 |
| End Date: | April 2016 |
Feasibility Study Evaluating Extraorally Delivered Low Level Light Therapy (LLLT) for the Prevention of Oropharyngeal Mucositis in Pediatric Patients Undergoing Myeloablative Hematopoietic Cell Transplantation
Oral mucositis (OM) is a painful and potentially debilitating acute toxicity that frequently
affects children undergoing hematopoietic cell transplantation (HCT). As a result of
intensive conditioning with chemotherapy with or without total body irradiation, and in the
case of allogeneic HCT, graft-versus-host disease (GVHD) prophylaxis, patients are at risk
for developing diffuse ulcerations of the oral and esophageal mucosa that result in pain and
suffering, increased utilization of opioid analgesics, and the need for intravenous or total
parenteral nutritional support. Patients universally report OM as being the worst aspect of
the HCT experience.A novel approach has been the use of larger light-emitting diode arrays
to treat the at risk tissues from an extraoral approach, enabling exposure of the oral,
oropharyngeal, and esophageal mucosa while avoiding the need for intraoral manipulation, and
requiring only minimal patient cooperation. In this research study, the investigators are
assessing the feasibility of providing extraorally delivered low level light therapy (LLLT)
for the prevention of OM in children undergoing myeloablative HCT.
affects children undergoing hematopoietic cell transplantation (HCT). As a result of
intensive conditioning with chemotherapy with or without total body irradiation, and in the
case of allogeneic HCT, graft-versus-host disease (GVHD) prophylaxis, patients are at risk
for developing diffuse ulcerations of the oral and esophageal mucosa that result in pain and
suffering, increased utilization of opioid analgesics, and the need for intravenous or total
parenteral nutritional support. Patients universally report OM as being the worst aspect of
the HCT experience.A novel approach has been the use of larger light-emitting diode arrays
to treat the at risk tissues from an extraoral approach, enabling exposure of the oral,
oropharyngeal, and esophageal mucosa while avoiding the need for intraoral manipulation, and
requiring only minimal patient cooperation. In this research study, the investigators are
assessing the feasibility of providing extraorally delivered low level light therapy (LLLT)
for the prevention of OM in children undergoing myeloablative HCT.
This is an open label, single treatment arm clinical pilot study. The study is targeted to
enroll twelve evaluable patients
OBJECTIVES:
Primary
- Determine the feasibility of providing extraoral LLLT for prevention of OM in pediatric
patients undergoing HCT
Secondary
- Determine the feasibility of collecting data using the WHO Oral Toxicity Scale and
ChIMES in pediatric patients undergoing myeloablative HCT who are treated with
extraoral LLLT for prevention of OM
- Evaluate the safety and tolerability of extraoral LLLT for prevention of OM in
pediatric patients undergoing myeloablative HCT
enroll twelve evaluable patients
OBJECTIVES:
Primary
- Determine the feasibility of providing extraoral LLLT for prevention of OM in pediatric
patients undergoing HCT
Secondary
- Determine the feasibility of collecting data using the WHO Oral Toxicity Scale and
ChIMES in pediatric patients undergoing myeloablative HCT who are treated with
extraoral LLLT for prevention of OM
- Evaluate the safety and tolerability of extraoral LLLT for prevention of OM in
pediatric patients undergoing myeloablative HCT
Inclusion Criteria:
- Scheduled to undergo myeloablative conditioning followed by autologous or allogeneic
hematopoietic cell transplantation at Boston Children's Hospital.
- 4 years of age to 25 years of age.
- WHO Oral Toxicity score of 0 at baseline evaluation (first day of conditioning).
- Ability to understand and the willingness to sign a written informed consent document
(for patients under the age of 18 this applies to parent/guardian)
- Ability to understand and/or the willingness of their parent or legally authorized
representative to sign a written informed consent document.
Exclusion Criteria:
- Treatment with oral LLLT within 4 weeks of HCT.
- Participants may not be receiving any other agents intended for the
prevention/management of mucositis (including palifermin and ice chips/cryotherapy).
- WHO ≥1 at baseline evaluation.
We found this trial at
2
sites
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
Click here to add this to my saved trials
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials